Could a custom vaccine help fight ovarian cancer?
NCT ID NCT02111941
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a personalized vaccine made from a patient's own immune cells to see if it is safe for people with advanced ovarian, fallopian tube, or peritoneal cancer. Nineteen participants who had already undergone surgery and chemotherapy received the vaccine. The main goal was to check for serious side effects and to see if the vaccine could stimulate an immune response against cancer cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized dendritic cell vaccine (loaded with folate receptor alpha peptides)
- What this could lead to
- If this vaccine proves safe and effective, it could offer a new way to help the immune system fight advanced ovarian cancer after standard treatments.
- What could go wrong
- This is a very early, small pilot study with only 19 participants. It primarily tests safety, not whether the vaccine actually controls the cancer. Many early-stage vaccines fail in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FALLOPIAN TUBE CLEAR CELL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill target Hard-to-Treat ovarian cancers?
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- New drug combo aims to improve ovarian cancer maintenance with fewer dropouts
- New hope for Platinum-Resistant ovarian cancer: ONC201 and paclitaxel combo trial launches
- Cancer drug combo tested for rare gene mutation – but trial stopped early
- Aerosol chemo spray shows promise for Hard-to-Treat ovarian cancer